<code id='67289C3995'></code><style id='67289C3995'></style>
    • <acronym id='67289C3995'></acronym>
      <center id='67289C3995'><center id='67289C3995'><tfoot id='67289C3995'></tfoot></center><abbr id='67289C3995'><dir id='67289C3995'><tfoot id='67289C3995'></tfoot><noframes id='67289C3995'>

    • <optgroup id='67289C3995'><strike id='67289C3995'><sup id='67289C3995'></sup></strike><code id='67289C3995'></code></optgroup>
        1. <b id='67289C3995'><label id='67289C3995'><select id='67289C3995'><dt id='67289C3995'><span id='67289C3995'></span></dt></select></label></b><u id='67289C3995'></u>
          <i id='67289C3995'><strike id='67289C3995'><tt id='67289C3995'><pre id='67289C3995'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:knowledge    Page View:438
          Three boxes of Wegovy stands in a line — coverage from STAT
          Steffen Trumpf/picture alliance/Getty Images

          LONDON — Starting in the new year, a team of researchers in the U.K. and Denmark will begin recruiting patients for a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice?

          Trials have demonstrated that the powerful drugs can help people shed weight in dramatic ways, but clinicians are still trying to sort out how to best use them. The medicines, after all, are pricey, come with side effects, and won’t work for everyone. And despite the excitement around these drugs, known as GLP-1s, some people might prefer or see better results with the other approaches that have long been the foundation of obesity treatment, from diet to surgery.

          advertisement

          “These drugs clearly are very effective, and that is fantastic,” said Susan Jebb, a professor of diet and population health at the University of Oxford and one of the leaders of the project. “But we have other options for treating obesity. What we need to do now in research is understand which treatments, for which patients, at which stage of their disease.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          At flashy new research hub, AstraZeneca lays out ambitious growth goals
          At flashy new research hub, AstraZeneca lays out ambitious growth goals

          PascalSoriothasservedasCEOofAstraZenecasince2012.WinMcNamee/GettyImagesCAMBRIDGE,England—Onabitofaro

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Liver decline slowed by off

          AdobeWASHINGTON—TherearethreeFDA-approveddrugsfortreatingalcoholusedisorder.Butadifferentmedication,